Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention

被引:34
作者
Mood, Girish R. [1 ]
Bavry, Anthony A. [1 ]
Roukoz, Henri [1 ]
Bhatt, Deepak L. [1 ]
机构
[1] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
关键词
D O I
10.1016/j.amjcard.2007.04.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Statin medications initiated during percutaneous coronary intervention have been evaluated in clinical trials mainly to assess if this therapy reduces subsequent restenosis. The benefit of statin therapy on individual cardiovascular outcomes other than restenosis is largely unknown. Hence, a meta-analysis of the available randomized trials was conducted to evaluate individual cardiovascular outcomes with statin therapy compared with placebo after elective percutaneous coronary intervention. In all, there were 6 studies available for analysis (Prevention of Restenosis by Elisor After Transluminal Coronary Angioplasty [PREDICT], Fluvastatin Angioplasty Restenosis [FLARE],. the Lescol Intervention Prevention Study [LIPS], German Atorvastatin Intravascular Ultrasound [GAIN], Atorvastatin for Reduction of Myocardial Damage During Angioplasty [ARMYDA], and a study by Briguori et al) that randomized 3,941 patients (1,967 to statins and 1,974 to placebos). Clinical follow-up ranged from 1 day to 45 months. The incidence of myocardial infarction was 3.0% in the statin group and 5.2% in the placebo group (odds ratio [OR] 0.57, 95% confidence interval [CI] 0.42 to 0.78, p < 0.0001). The incidence,of all-cause mortality was 2.3% versus 3.0% (OR 0.74, 95% CI 0.50 to 1.1, p = 0.14), that of cardiovascular mortality was 0.71% versus 1.2% (OR 0.58, 95% CI 0.30 to 1.11, p = 0.10), and that of repeat surgical or percutaneous revascularization was 19.6% versus 21.9% (OR 0.89, 95% CI 0.78 to 1.02, p = 0.098) in the statin arm versus the placebo arm, respectively. The incidence of stroke was 0.4% in the statin arm and 0.08% in the placebo arm (OR 3.00, 95% CI 0.60 to 14.77, p = 0.18). In conclusion, statin therapy initiated at the time of elective percutaneous coronary intervention significantly reduces myocardial infarction. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:919 / 923
页数:5
相关论文
共 20 条
[1]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[2]   Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome - A systematic review of Randomized trials [J].
Bavry, Anthony A. ;
Mood, Girish R. ;
Kumbhani, Dharam J. ;
Borek, Peter P. ;
Askari, Arman T. ;
Bhatt, Deepak L. .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (02) :135-141
[3]   Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty [J].
Bertrand, ME ;
McFadden, EP ;
Fruchart, JC ;
VanBelle, E ;
Commeau, P ;
Grollier, G ;
Bassand, JP ;
Machecourt, J ;
Cassagnes, J ;
Mossard, JM ;
Vacheron, A ;
Castaigne, A ;
Danchin, N ;
Lablanche, JM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (04) :863-869
[4]   Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes [J].
Bhatt, DL ;
Topol, EJ .
CIRCULATION, 2005, 112 (06) :906-915
[5]   Need to test the arterial inflammation hypothesis [J].
Bhatt, DL ;
Topol, EJ .
CIRCULATION, 2002, 106 (01) :136-140
[6]   Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy) [J].
Blankenship, JC ;
Haldis, T ;
Feit, F ;
Hu, TF ;
Kleiman, NS ;
Topol, EJ ;
Lincoff, AM .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (11) :1591-1596
[7]   Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction [J].
Briguori, C ;
Colombo, A ;
Airoldi, F ;
Violante, A ;
Focaccio, A ;
Balestrieri, P ;
Elia, PP ;
Golia, B ;
Lepore, S ;
Riviezzo, G ;
Scarpato, P .
EUROPEAN HEART JOURNAL, 2004, 25 (20) :1822-1828
[8]   Relation of inflammation and benefit of statins after percutaneous coronary interventions [J].
Chan, AW ;
Bhatt, DL ;
Chew, DP ;
Reginelli, J ;
Schneider, JP ;
Topol, EJ ;
Ellis, SG .
CIRCULATION, 2003, 107 (13) :1750-1756
[9]   Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention [J].
Chan, AW ;
Bhatt, DL ;
Chew, DP ;
Quinn, MJ ;
Moliterno, DJ ;
Topol, EJ ;
Ellis, SG .
CIRCULATION, 2002, 105 (06) :691-696
[10]   Effects of HMG-CoA reductase inhibitors on endothelial function - Role of microdomains and oxidative stress [J].
Mason, RP ;
Walter, MF ;
Jacob, RF .
CIRCULATION, 2004, 109 (21) :34-41